Hendricks, Oliver https://orcid.org/0000-0001-9473-5072
Andersen, Tonny Elmose https://orcid.org/0000-0002-9045-7500
Christiansen, Afshin Ashouri
Hauge, Ellen Margrethe https://orcid.org/0000-0003-2562-9174
Horsted, Tina Ingrid
Hansen, Philip Rask Lage https://orcid.org/0000-0002-1449-254X
Bojesen, Anders Bo https://orcid.org/0000-0002-5321-6855
Nabi, Hafsah https://orcid.org/0000-0001-6331-7927
Wieghorst, Anders https://orcid.org/0000-0002-4788-9463
Østergaard, Mikkel https://orcid.org/0000-0003-3690-467X
Hetland, Merete Lund https://orcid.org/0000-0003-4229-6818
Krogh, Niels Steen https://orcid.org/0000-0002-8520-1674
Roessler, Kirsten Kaya https://orcid.org/0000-0001-6605-7999
Hørslev-Petersen, Kim https://orcid.org/0000-0002-5475-7610
Funding for this research was provided by:
University of Southern Denmark
Article History
Received: 5 April 2026
Accepted: 25 August 2026
First Online: 31 August 2026
Declarations
Ethics approval and consent to participate: All participants received detailed verbal and written information about the study and provided written informed consent before enrolment, following Danish Ethics Committee guidelines. The cannabis compounds used in the study are comparable to Sativex, an authorized drug in Denmark, and patients were informed about expected efficacy and side effects (Borgelt et al. 2013; Martin-Santos et al. 2012; 2025; Winton-Brown et al. 2011).Study drugs were produced under strict quality control according to Danish Good Clinical Practice (GCP) standards. Safety oversight was provided by an independent GCP unit at the University of Southern Denmark. The study adheres to the Declaration of Helsinki and local regulations and received approval from the Danish Ethics Committee (S-20170217), the Danish Data Protection Agency (2018–41-5388), and the Danish Medicines Agency (2018–010018).
Consent for publication: Not applicable.
Competing interests: The authors declare that they have no competing interests.